A groundbreaking NIH-funded study reveals that young athletes may experience significant brain changes long before chronic traumatic encephalopathy (CTE) becomes detectable, highlighting the urgent need for early diagnosis and treatment.
Cracker Barrel's customer visits plummet by 8% following a controversial logo change. The chain faces continued decline, prompting a reevaluation of its transformation plans and marketing investments.
Isabel Kallman grapples with perimenopause symptoms and the decision to consider hormone therapy. Experts argue that the risks associated with treatment may have been overstated, calling for a reevaluation of FDA warnings.
The assassination of conservative activist Charlie Kirk sends shockwaves through the nation. As investigators delve into the suspect's background, disturbing connections to gaming and dark internet culture surface, raising alarm over political violence.
Lendbuzz, the auto finance fintech, has filed for an IPO aiming for a valuation of $1.5 billion. As it joins a wave of fintech companies going public, will it succeed where others falter?
Klarna's long-awaited IPO has finally arrived, raising $1.4 billion on the NYSE. With shares initially soaring to $52, the fintech giant marks a significant milestone in its journey from a daring startup to a $15 billion valuation. Find out how existing investors played a key role in this success!
Tesla's Board has unveiled a groundbreaking pay package for Elon Musk that ties his potential earnings to the company's ambitious $8.5 trillion valuation. Discover the implications!
NASA's new Mission Evaluation Room at the Johnson Space Center enhances monitoring for Artemis 2, the crewed flight test of the Orion spacecraft. With 24/7 data analysis, this facility ensures safety and paves the way for future lunar missions.
As Nvidia prepares to report quarterly results, the tech giant's impact on the S&P 500 and AI stock valuations is under scrutiny. Investors brace for possible market shifts amid concerns of an AI bubble.
In a surprising move, the CDC has appointed Retsef Levi, an anti-vaccine advocate, to lead a new COVID vaccine review group, raising concerns about the integrity of the review process. Experts fear the group may lack rigorous scientific standards.
